These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

103 related articles for article (PubMed ID: 26415289)

  • 1. [THE DIFFICULTY IN DIAGNOSING OF RARE FORMS OF CONGENITAL DISORDERS OF AMINO ACID METABOLISM IN INFANTS (HEREDITARY TYROSINEMIA)].
    Melnikova NI; Kartseva EV; Kirsanov AS; Strogonov IA; Ageeva LN; Kharitonova GD; Olhova EB; Belyaeva TY
    Anesteziol Reanimatol; 2015; 60(3):16-9. PubMed ID: 26415289
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Diagnosis of hereditary tyrosinemia type I: clinical study of ten patients].
    Li XY; DU ML; Zhuang SQ
    Zhonghua Er Ke Za Zhi; 2006 Jun; 44(6):470-1. PubMed ID: 16836864
    [No Abstract]   [Full Text] [Related]  

  • 3. [One case of hereditary tyrosinemia type I].
    Huang YL; Li XJ; Luo XP; Wei H; Song YY
    Zhonghua Er Ke Za Zhi; 2003 Apr; 41(4):309. PubMed ID: 14754550
    [No Abstract]   [Full Text] [Related]  

  • 4. Neonatal presentation of a rare metabolic liver disease.
    David JJ; Tullu MS; Rathi P; Sawalakhe N; Ghildiyal RG
    Trop Gastroenterol; 2008; 29(4):229-31. PubMed ID: 19323095
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The pathophysiology and treatment of hereditary tyrosinemia type 1.
    Grompe M
    Semin Liver Dis; 2001 Nov; 21(4):563-71. PubMed ID: 11745044
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Neonatal hemochromatosis: a case report with unique presentation.
    Cakir M; Mutlu M; Aydin-Mungan S; Cansu A; Aslan Y; Erduran E
    Turk J Pediatr; 2011; 53(4):455-9. PubMed ID: 21980852
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tyrosinemia type 1 and irreversible neurologic crisis after one month discontinuation of nitisone.
    Önenli Mungan N; Yıldızdaş D; Kör D; Horoz ÖÖ; İncecik F; Öktem M; Sander J
    Metab Brain Dis; 2016 Oct; 31(5):1181-3. PubMed ID: 27188289
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Persistent tyrosinemia detected by thin-layer chromatography.
    Neto EC; Schulte J; Anele E; Becker D; Rubim R; Lewis E; De Mari J; Giugliani R
    Southeast Asian J Trop Med Public Health; 1999; 30 Suppl 2():151. PubMed ID: 11400756
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Clinical, biochemical and molecular characteristics in 11 Czech children with tyrosinemia type I].
    Vondrácková A; Tesarová M; Magner M; Docekalová D; Chrastina P; Procházkova D; Zeman J; Honzík T
    Cas Lek Cesk; 2010; 149(9):411-6. PubMed ID: 21117323
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The successful inclusion of succinylacetone as a marker of tyrosinemia type I in Tuscany newborn screening program.
    la Marca G; Malvagia S; Funghini S; Pasquini E; Moneti G; Guerrini R; Zammarchi E
    Rapid Commun Mass Spectrom; 2009 Dec; 23(23):3891-3. PubMed ID: 19902423
    [No Abstract]   [Full Text] [Related]  

  • 11. Significant increase of succinylacetone within the first 12 h of life in hereditary tyrosinemia type 1.
    Schlump JU; Mayatepek E; Spiekerkoetter U
    Eur J Pediatr; 2010 May; 169(5):569-72. PubMed ID: 19813022
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Goldenhar syndrome and hereditary tyrosinemia type 1.
    Al-Sayed MA; Asmari AM; Rashed MS
    Saudi Med J; 2002 Dec; 23(12):1527-31. PubMed ID: 12518207
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hepatocellular carcinoma in tyrosinemia type 1 without clear increase of AFP.
    van Ginkel WG; Gouw AS; van der Jagt EJ; de Jong KP; Verkade HJ; van Spronsen FJ
    Pediatrics; 2015 Mar; 135(3):e749-52. PubMed ID: 25667247
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Update on pathogenesis, diagnosis and treatment of hereditary tyrosinemia type Ⅰ].
    Jin SJ; Du CQ; Luo XP
    Zhonghua Er Ke Za Zhi; 2022 Jun; 60(6):604-607. PubMed ID: 35658373
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hepatorenal Tyrosinemia in Mexico: A Call to Action.
    Ibarra-González I; Ridaura-Sanz C; Fernández-Lainez C; Guillén-López S; Belmont-Martínez L; Vela-Amieva M
    Adv Exp Med Biol; 2017; 959():147-156. PubMed ID: 28755193
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Tyrosinemia type II. Case report].
    Benatiya AI; Bouayed MA; Touiza E; Daoudi K; Bhalil S; Elmesbahi I; Tahri H
    Bull Soc Belge Ophtalmol; 2005; (296):57-61. PubMed ID: 16050420
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Biochemical and molecular diagnosis of tyrosinemia type I with two novel FAH mutations in a Hong Kong chinese patient: recommendation for expanded newborn screening in Hong Kong.
    Mak CM; Lam CW; Chim S; Siu TS; Ng KF; Tam S
    Clin Biochem; 2013 Jan; 46(1-2):155-9. PubMed ID: 23000314
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The inclusion of succinylacetone as marker for tyrosinemia type I in expanded newborn screening programs.
    la Marca G; Malvagia S; Pasquini E; Innocenti M; Fernandez MR; Donati MA; Zammarchi E
    Rapid Commun Mass Spectrom; 2008; 22(6):812-8. PubMed ID: 18278819
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Neurological crisis mimicking acute pancreatitis in tyrosinemia type I.
    Kalkanoğlu HS; Coşkun T
    Turk J Pediatr; 1999; 41(4):501-4. PubMed ID: 10770119
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Recommendations and management of type I hereditary or hepatorenal tyrosinemia].
    Couce ML; Aldámiz-Echevarría L; Baldellou A; Blasco J; Bueno MA; Dalmau J; De La Vega A; Del Toro M; Díaz C; Lama R; Leao E; Marrero M; Navas VM; Pintos G
    An Pediatr (Barc); 2010 Nov; 73(5):279.e1-4. PubMed ID: 20813594
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.